Heterogeneity Maintenance in Glioblastoma: A Social Network

被引:349
作者
Bonavia, Rudy [1 ]
Inda, Maria-del-Mar [4 ]
Cavenee, Webster K. [2 ,3 ,4 ]
Furnari, Frank B. [2 ,3 ,4 ]
机构
[1] Univ Calif San Diego, Dept Pathol, La Jolla, CA 92093 USA
[2] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA
[3] Univ Calif San Diego, Sch Med, Moores Canc Ctr, La Jolla, CA 92093 USA
[4] Univ Calif San Diego, Ludwig Inst Canc Res, La Jolla, CA 92093 USA
关键词
HUMAN GLIOMA-CELLS; ASTROCYTIC TUMORS; GROWTH-FACTOR; EXPRESSION; CANCER; SUBPOPULATIONS; MALIGNANCY; AUTOCRINE; INDUCTION; RECEPTOR;
D O I
10.1158/0008-5472.CAN-11-0153
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Glioblastoma multiforme (GBM), the most common intracranial tumor in adults, is characterized by extensive heterogeneity at the cellular and molecular levels. This insidious feature arises inevitably in almost all cancers and has great significance for the general outcome of the malignancy, because it confounds our understanding of the disease and also intrinsically contributes to the tumor's aggressiveness and poses an obstacle to the design of effective therapies. The classic view that heterogeneity arises as the result of a tumor's "genetic chaos" and the more contemporary cancer stem cell (CSC) hypothesis tend to identify a single cell population as the therapeutic target: the prevailing clone over time in the first case and the CSC in the latter. However, there is growing evidence that the different tumor cell populations may not be simple bystanders. Rather, they can establish a complex network of interactions between each other and with the tumor microenvironment that eventually strengthens tumor growth and increases chances to escape therapy. These differing but complementary ideas about the origin and maintenance of tumor heterogeneity and its importance in GBM are reviewed here. Cancer Res; 71(12); 4055-60. (C)2011 AACR.
引用
收藏
页码:4055 / 4060
页数:6
相关论文
共 39 条
[11]   DNA Damage-Mediated Induction of a Chemoresistant Niche [J].
Gilbert, Luke A. ;
Hemann, Michael T. .
CELL, 2010, 143 (03) :355-366
[12]   Cancer stem cells: Back to Darwin? [J].
Greaves, Mel .
SEMINARS IN CANCER BIOLOGY, 2010, 20 (02) :65-70
[13]  
Harada K, 1998, CANCER RES, V58, P4694
[14]   Correlation of O6-Methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity [J].
Hegi, Monika E. ;
Liu, Lili ;
Herman, James G. ;
Stupp, Roger ;
Wick, Wolfgang ;
Weller, Michael ;
Mehta, Minesh P. ;
Gilbert, Mark R. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (25) :4189-4199
[15]  
HERMANSON M, 1992, CANCER RES, V52, P3213
[16]   Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment [J].
Hoelzinger, Dominique B. ;
Demuth, Tim ;
Berens, Michael E. .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (21) :1583-1593
[17]   The enhanced tumorigenic activity of a mutant epidermal growth factor receptor common in human cancers is mediated by threshold levels of constitutive tyrosine phosphorylation and unattenuated signaling [J].
Huang, HJS ;
Nagane, M ;
Klingbeil, CK ;
Lin, H ;
Nishikawa, R ;
Ji, XD ;
Huang, CM ;
Gill, GN ;
Wiley, HS ;
Cavenee, WK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (05) :2927-2935
[18]   Genetically Engineered Mouse Models of Brain Cancer and the Promise of Preclinical Testing [J].
Huse, Jason T. ;
Holland, Eric C. .
BRAIN PATHOLOGY, 2009, 19 (01) :132-143
[19]   Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma [J].
Inda, Maria-del-Mar ;
Bonavia, Rudy ;
Mukasa, Akitake ;
Narita, Yoshitaka ;
Sah, Dinah W. Y. ;
Vandenberg, Scott ;
Brennan, Cameron ;
Johns, Terrance G. ;
Bachoo, Robert ;
Hadwiger, Philipp ;
Tan, Pamela ;
DePinho, Ronald A. ;
Cavenee, Webster ;
Furnari, Frank .
GENES & DEVELOPMENT, 2010, 24 (16) :1731-1745
[20]   Cells with TP53 mutations in low grade astrocytic tumors evolve clonally to malignancy and are an unfavorable prognostic factor [J].
Ishii, N ;
Tada, M ;
Hamou, MF ;
Janzer, RC ;
Meagher-Villemure, K ;
Wiestler, OD ;
de Tribolet, N ;
Van Meir, EG .
ONCOGENE, 1999, 18 (43) :5870-5878